The more detailed knowledge of the minimal HS/heparin sequence necessary for recognition and cleavage by heparanase facilitates the design of inhibitors of the enzyme and is expected to boost active research in the field also by other groups when the information will be released.  Prototypes of novel heparanase inhibitors were already found to be active as antiangiogenic/ antimetastatic agents in animal models as least as the previously described heparanase inibitors and some of them promise to be more bioavailable than the established ones. A number of  pharmaceutical companies  are expected to benefit from information and products generated by the project even beyond applications in oncology.